COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00765973
Recruitment Status : Completed
First Posted : October 3, 2008
Last Update Posted : November 13, 2020
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc

Brief Summary:

A multi-center, open-label, two-arm, dose-escalation study to establish the safety, tolerability, MTD, and schedule of TLI administered intravenously as a 30 minute infusion in adult subjects with advanced solid tumors that have relapsed, are refractory to standard therapy, or for whom there is no standard therapy available.

The two dosing regimens to be evaluated are:

  • Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
  • Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)

When one of the two arms reaches MTD, all future subjects will then be enrolled in the remaining study arm until MTD of that arm is reached.

Condition or disease Intervention/treatment Phase
Small Cell Lung Cancer Ovarian Cancer Solid Tumors Drug: Topotecan Liposomes Injection (TLI) Phase 1

Detailed Description:

The study will utilize an accelerated design with small initial cohort sizes that allow fewer subjects to be enrolled at sub-therapeutic doses such as the very low starting doses in both arms of the study. Initial cohorts will include only one subject and dose escalations will be in 100% increments until a single Grade 2 toxicity related to study drug or DLT occurs in Cycle 1. Dose escalation will proceed until the MTD is exceeded. MTD is defined as average of the highest dose level for which 2 out of 6 subjects experience a DLT and the previous dose level, provided no additional DLTs occur. Subjects who discontinue TLI treatment before completion of Cycle 1 for reasons other than toxicity will not be evaluable for the determination of MTD and will be replaced.

The study will consist of a screening period, treatment period, and a post-treatment period. Subjects will be followed for 30 days after their last TLI dose. Safety and tolerability parameters include clinical laboratory assessments, vital signs, physical examinations, and adverse events (AEs).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Topotecan Liposomes Injection (TLI) in Subjects With Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors
Actual Study Start Date : November 10, 2008
Actual Primary Completion Date : June 30, 2010
Actual Study Completion Date : June 30, 2010

Arm Intervention/treatment
Experimental: A
Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
Drug: Topotecan Liposomes Injection (TLI)
TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)

Experimental: B
Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
Drug: Topotecan Liposomes Injection (TLI)
TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)

Primary Outcome Measures :
  1. Evaluate the safety, tolerability and maximum tolerated dose of 2 different dosing schedules of TLI administered intravenously [ Time Frame: 21 days following initial dose ]

Secondary Outcome Measures :
  1. Assess the pharmacokinetic profile of TLI [ Time Frame: 21 Day Cycle ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Histologically or cytologically confirmed advanced solid tumor that has relapsed, is refractory to standard treatment, or for whom there is no standard therapy available.
  3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  4. Normal organ and marrow function as defined below within 14 days of study entry

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    2. Platelet count ≥100 x 109/L
    3. Hemoglobin ≥ 9 g/dL
    4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN), or 5 x ULN for subjects with liver metastases
    6. Serum creatinine ≤ 1.5 x ULN or calculated estimated creatinine clearance ≥ 50 mL/min/1.73m2 for subjects with creatinine levels above institutional normal based on the Cockcroft and Gault formula.
  5. Never received prior TLI or topotecan HCl (Hycamtin®)
  6. At least 4 weeks must have elapsed from the last dose of chemotherapy.
  7. Life expectancy ≥ 3 months
  8. Women of childbearing potential must have a negative urine or blood pregnancy test within 7 days prior to initiation of treatment.
  9. If female, subject is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (e.g., hormonal contraceptive, intra-uterine device (IUD), diaphragm with spermicide, condom with spermicide or abstinence) from the screening visit through the duration of study participation.
  10. If male, subject agrees to use an acceptable barrier method for contraception from the screening visit though the duration of study participation.
  11. Before enrollment, the subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign a written informed consent according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

  1. Use of any investigational drugs, biologics, or devices within 28 days prior to study treatment or planned use during the course of the study.
  2. Primary tumors of central nervous system (CNS). Symptomatic brain metastases (unless subject is stable without requirement of steroids and/or antiseizure medications for at least three months) or leptomeningeal tumor involvement. Imaging studies are not required to rule this out unless there is a clinical suspicion of CNS disease.
  3. Prior chemotherapy or radiotherapy within 4 weeks of Day 1 of study (6 weeks for nitrosureas or mitomycin C).
  4. Planned concurrent systemic therapy (cytotoxic and/or cytostatic) and/or radiotherapy during study treatment.
  5. Less than 4 weeks have elapsed from the time of major surgery.
  6. Subjects with a history of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to TLI, including known allergies to the ingredients comprising the liposome (e.g., cholesterol and/or sphingomyelin), which in the Investigator's opinion may put the subject at risk for significant reaction to the study drug.
  7. Subjects who are pregnant or lactating.
  8. Subjects known to be positive for human immunodeficiency virus (HIV), hepatitis C antibody, or hepatitis B surface antigen.
  9. Prophylactic hematologic growth factors administered ≤ 2 weeks prior to start of treatment with TLI (excluding darbepoetin alfa and epoetin alfa).
  10. Active infection or any serious underlying medical condition, which would impair the ability of the subject to receive protocol treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00765973

Layout table for location information
United States, Michigan
Barbara Ann Karmanos Cancer Center
Detroit, Michigan, United States, 48201
United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Spectrum Pharmaceuticals, Inc
Layout table for additonal information
Responsible Party: Spectrum Pharmaceuticals, Inc Identifier: NCT00765973    
Other Study ID Numbers: HBS601
First Posted: October 3, 2008    Key Record Dates
Last Update Posted: November 13, 2020
Last Verified: November 2020
Keywords provided by Spectrum Pharmaceuticals, Inc:
Other Advanced Solid Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Bronchogenic
Bronchial Neoplasms
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents